
NRSN Stock Forecast & Price Target
NRSN Analyst Ratings
Bulls say
NeuroSense Therapeutics Ltd is positioned favorably for strategic partnerships due to converging regulatory and clinical milestones, particularly in North America and Europe. The company's PrimeC candidate has demonstrated a statistically significant 29.2% slowing of disease progression in its Phase 2b PARADIGM study, with even greater benefits noted for early treatment cohorts, highlighting its therapeutic potential. Additionally, the favorable safety and tolerability profile, along with biomarker-driven evidence of target engagement, reinforces the company's outlook as it prepares for late-stage activities and potential collaborations that could provide non-dilutive capital.
Bears say
NeuroSense Therapeutics Ltd is facing significant financial challenges as indicated by tightening cash reserves, which raises concerns about the company's liquidity and operational sustainability. The anticipated need for a capital raise suggests potential difficulties in funding ongoing clinical trials and development efforts for its product candidate, PrimeC, aimed at treating neurodegenerative diseases. As a result, these issues may hinder investor confidence and negatively impact the stock's performance in the market.
This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.
NRSN Analyst Forecast & Price Prediction
Start investing in NRSN
Order type
Buy in
Order amount
Est. shares
0 shares